Author： DeLucca P.
Publisher： Oxford University Press
ISSN： 1465-4644
Source： Biostatistics, Vol.1, Iss.1, 2000-03, pp. : 107-111
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
When using subjective ordered categorical variables to measure the efficacy of an active treatment versus placebo in a double-blind clinical trial setting, bias may be introduced into the response variables when investigators become partially or totally unblinded to treatment assignment due to characteristic side effects. The investigators may alter the classification of a patient’s response to treatment based on perceived treatment assignment. The introduction of bias leads to a considerable increase in the actual significance level of the Wilcoxon rank-sum test.
Related content
Access to resources
Recommend
Insights on bias and information in group-level studies
By Sheppard L.
Biostatistics, Vol. 4, Iss. 2, 2003-04 ,pp. :
JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 13, Iss. 5, 1965-05 ,pp. :